

Electronic Acknowledgement Receipt

EFS ID:	1587669
Application Number:	10567801
International Application Number:	
Confirmation Number:	3056
Title of Invention:	Heterocyclic amide derivatives which process glycogen phosphorylase inhibitory activity
First Named Inventor/Applicant Name:	Stuart Norman Lile Bennett
Customer Number:	44992
Filer:	Lucy Clare Padgett
Filer Authorized By:	
Attorney Docket Number:	101181-1P US
Receipt Date:	13-MAR-2007
Filing Date:	09-FEB-2006
Time Stamp:	14:35:44
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2321
Deposit Account	503231
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part /.zip	Pages (if appl.)
1		101181ResponsetoRestrictionRequirement.pdf	139087	yes	10
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Response to Election / Restriction Filed		1	1	
	Claims		2	8	
	Applicant Arguments/Remarks Made in an Amendment		9	10	
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed	101181IDS.pdf	801916	no	4
Warnings:					
Information:					
A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.					
3	NPL Documents	101181BritJPharmacpaper.pdf	186499	no	11
Warnings:					
Information:					
4	Fee Worksheet (PTO-06)	fee-info.pdf	8230	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			1135732		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.